Publications by authors named "Kristen A Shimko"
Background: Basiliximab is a high-cost induction agent typically given as two doses in liver transplant recipients. This study evaluated renal outcomes in live-donor liver transplant recipients (LDLTRs) with stable renal function at the time of transplant receiving one versus two doses of basiliximab.
Methods: We retrospectively identified 231 adult LDLTR with a serum creatinine (SCr) <1.